Bility is
an bionic limb
and Bio-robotics
Physical AI center

The opportunity

Significant weaknesses in current products

Current Bionic Limb products impose a set of difficulties, discomforts and lack of functionality and human awareness on their users

Growing global
demand

Higher rates of limb amputations due to the global diabetes surge and evolving conflicts and wars around the world highlight the growing need for much better bionic limbs than currently exist.

Harnessing Physical AI and advanced technologies

Rapid technological and scientifical advancements in various disciplines, such as Physical AI, materials science, robotics, and bio-technology, offer unprecedented opportunities to improve bionic limb and bio-robotic functionality, usability and comfort

Innovative Bionic Limbs Conceptual Model

We designed a ground-breaking conceptual model of next-generation bionic limbs, which meticulously defined the functions, principles of action and technology pathway to enable the development of superior next-generation bionic limbs. Our Conceptual model will direct and inspire our synergistic R&D effort.
Discover more

Synergistic R&D

Our unique Synergistic R&D framework interwinds internal core R&D and collaborative R&D with added valued partners, which together will reinforce and accelerate the development and commercialization of next-generation bionic limbs.

Internal

Core R&D

Conducted by four groups of developers, engineers and scientists focused on developing core bio-robotics technologies.
Human Locomotion Big Data & Physical AI Group
Bio-Robotics Operating System Group
Functional Materials Group
Prototype Engineering Group
Discover more
External

Collaborative R&D

Multidisciplinary R&D collaboration framework that will allow to work with added value expert partners in different fields jointly.
Collaborative R&D
Discover more

How we do it

Our unique 
business model

We will develop and monetize
the following Assets:
01

Human Locomotion Big Data

We will sell licenses to use our human locomotion big data, data generator and collaborative AI infrastructure to research institutes and commercial clients.

02

Bio-Robotics Operating System

We will implement an annual license fee model to monetize our proprietary Operating System, targeting related industries, market leaders and academic research groups.

03

Partnerships & Startups

Following our collaborations, we will partner as equity investors in related commercially attractive startups, providing seed investments and R&D Resources.

04

Proprietary and collaborative
intellectual properties

We will license our proprietary and collaborative technologies and IP to clients of interest in a broad spectrum of related industries.

The brains behind

Meet our leadership

Ido Merfeld, PhD

Founder & Chairman

Dr. Ido Merfeld, founder, holds a PhD in molecular biology with a specialty in neuroscience and a BA in computer science, economy and statistics. Dr. Merfeld co-founded and acted as CEO and chairman of Ivory Software Systems, a successful FinTech company based in Israel. Dr. Merfeld has also been involved in the establishment of several other startup companies and projects globally.

Yishay Falick, MD MBA

CEO

Dr. Yishay Falick is a physician-executive with extensive leadership across healthcare, government, and advanced technologies. He has served as Chairman of the Israeli Biochip Generic Technology Consortium, Director of HealthTech and Bioconvergence innovation at Israel Aerospace Industries, and CEO of a public hospital. An expert in ophthalmic stem cell reconstructive surgeries and licensed health systems management professional, he bridges clinical excellence with strategic innovation.

Erez Morag, PhD

VP Bio-mechanics

An accomplished innovation executive with over 20 years of leadership experience in human locomotion holding a PhD in Biomechanics. Expertise includes developing cutting-edge products, such as footwear and wearables, tailored for diverse populations ranging from youth to elite athletes.

Prof. Sharon Gerecht

Advisory Board Member

Prof. Sharon Gerecht is the Paul M. Gross Distinguished Professor and chair of Biomedical Engineering at Duke. Prof. Gerecht is an internationally recognized leader in stem cell and vascular biology and engineering. Her research examines how the tissue microenvironment, including mechanical forces and oxygen availability, shapes blood vessel function in health, aging, and disease. Before joining Duke, she was the Edward J. Schaefer Professor at Johns Hopkins University and director of its Institute for NanoBioTechnology. She is a fellow of AAAS, AIMBE, and the American Heart Association and a member of the National Academy of Inventors and the National Academy of Medicine.

Michal Fraifeld

VP Product Design

Design and Innovation Manager with a Master's (M.Des) and a Bachelor's in Industrial Design (B.Des) from Bezalel Academy of Art and Design.
The owner of a studio that specializes in design research and product design. Additionally, a senior lecturer in the Industrial Design Department at Shenkar College.

The broad context

Our supporters